EBay forecast current-quarter revenue below Wall Street estimates on Wednesday, as it faces fierce competition from bigger rivals Amazon.com and Walmart in the run-up to the crucial holiday shopping season.
Xilinx Inc on Wednesday forecast current-quarter and full-year revenue below Wall Street estimates, the second major chipmaker this week to flag the impact of a prolonged U.S.-China trade dispute on its business.
The Instagram age has given rise to a new class — the “influencers”, who persuade their followers to buy and think in certain ways. But the biggest influencer of the lot is Facebook, says the Financial Times' Gideon Rachman.
Johnson & Johnson on Wednesday lowered its previously reported profit for the third quarter to US$1.8 billion from US$4.8 billion to account for a proposed opioid settlement payment.
Alphabet Inc's Google said on Wednesday it achieved a breakthrough in computing research by using a quantum computer to solve in minutes a complex problem that would take today's most powerful supercomputer thousands of years to crack.
Microsoft reported Wednesday quarterly profits rose on the back of its thriving cloud computing business which has become a core focus for the US technology giant.
The Federal Aviation Administration (FAA) must work to restore "public confidence" in aircraft certification efforts after two deadly Boeing 737 MAX crashes, the U.S. Transportation Department's inspector general said Wednesday in a report seen by Reuters.
Wall Street was supported by gains in Apple and Boeing shares on Wednesday, though weak earnings from Caterpillar and Texas Instruments raised concerns of an impact from the U.S.-China trade war on global growth.
Brazil's federal audits court on Wednesday approved a draft contract for a massive transfer of rights oil deal between state-run oil firm Petroleo Brasileiro SA , better known as Petrobras, and the government.
Teva Pharmaceutical Industries Ltd's proposed US$23 billion drug giveaway to settle thousands of U.S. opioid lawsuits will likely cost the company a fraction of that figure due to how it has valued those medicines, according to a Reuters review of pricing data and industry analysts.
